Deal Watch: Allergan Deal-Binge Includes Derm, NASH Buys
Golden Meditech and MD Anderson establish startup focused on umbilical cord blood-derived T-regulatory therapies. Bayer and Evotec sign their second collaboration in four years, this time focused on renal disease.
You may also be interested in...
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.